SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV)
SKBI
SKBI was delisted on the 18th of December, 2015.
1 hedge funds and large institutions have $8K invested in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) in 2015 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 9 closing their positions.
90% less funds holding
Funds holding: 10 → 1 (-9)
98% less capital invested
Capital invested by funds: $426K → $8K (-$418K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 9
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$167K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$141K |
| 3 |
Renaissance Technologies
New York
|
-$50K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$22K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$17K |
SKBI Hedge Fund Activity: Q4 2015 in Review
1 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) for Q4 2015, worth a combined $8K — down 98% from $426K a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of SKBI and 0 opened new positions — a net loss of 9 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock Institutional Trust, exiting entirely with an estimated $167K sold.
- 1 institutional investor held SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) as of Q4 2015, down from 10 in Q3 2015.
- Funds reported $8K of SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) stock for Q4 2015, down 98% quarter-over-quarter.
- 0 funds opened new SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) positions in Q4 2015 and 9 closed out, a net change of -9 holders.
- The largest SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) seller in Q4 2015 was BlackRock Institutional Trust, an estimated $167K sold.
Based on aggregated 13F filings for Q4 2015.